Merck announces Phase 3 trial initiations for 4 Investigational Candidates from hematology and oncology pipeline
Comprehensive clinical development programs being initiated for each investigational candidate
Comprehensive clinical development programs being initiated for each investigational candidate
Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers
Subscribe To Our Newsletter & Stay Updated